Holen Sie sich die Stockscreener-App
294.38
0.60%
1.75
Handel nachbörslich:
295.00
0.62
+0.21%
Schlusskurs vom Vortag:
$292.63
Offen:
$285.22
24-Stunden-Volumen:
821.13K
Relative Volume:
0.80
Marktkapitalisierung:
$7.42B
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-32.10
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
-0.12%
1M Leistung:
+8.64%
6M Leistung:
+529.56%
1J Leistung:
+299.54%
1-Tages-Spanne:
$282.00
$302.34
1-Wochen-Bereich:
$268.78
$302.34
52-Wochen-Spanne:
$26.70
$317.72
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
294.38 | 7.37B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Will Praxis Precision Medicines Inc. stock benefit from commodity pricesJuly 2025 Volume & Real-Time Market Sentiment Alerts - ulpravda.ru
Will Praxis Precision Medicines Inc. stock reach all time highs in 2025 - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a smart buy before Fed meeting2025 Technical Patterns & Expert Approved Trade Ideas - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a buy in volatile marketsJuly 2025 EndofMonth & Capital Efficient Trade Techniques - ulpravda.ru
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status - MSN
PRAX Stock Surge: Time to Buy? - StocksToTrade
Praxis Precision Medicines Announces Major Underwritten Equity Offering - TipRanks
Praxis Precision Medicines Announces Underwritten Offering - TradingView — Track All Markets
Praxis Precision Medicines (PRAX) Valuation Check After A Strong 90 Day Share Price Run - Yahoo Finance
Praxis Precision stock rises as $575 million share sale clears at $260 - TechStock²
Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Praxis Precision Prices $575 Mln Public Offering At $260/shr - Nasdaq
Praxis Precision (PRAX) Announces Public Offering of Stock and W - GuruFocus
Praxis Precision Medicines (PRAX) Announces $575M Public Offerin - GuruFocus
Praxis Precision prices $575M stock offering at $260 - MSN
Praxis Precision Medicines prices public offering at $260 per share By Investing.com - Investing.com Australia
Praxis Precision Medicines prices public offering at $260 per share - Investing.com
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - Yahoo Finance
Praxis Precision Medicines Announces Pricing of Public Offering of Common Stock at $260 Per Share - Quiver Quantitative
Biotech targeting CNS disorders lines up $575M stock sale - Stock Titan
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - GlobeNewswire Inc.
Praxis Precision Medicines reports preliminary $925 million in cash and securities By Investing.com - Investing.com South Africa
Praxis Precision Medicines reports preliminary $925 million in cash and securities - Investing.com
After-hours movers: Strategy, Mobileye, Ventyx Bioscience, Praxis - Investing.com
Praxis Precision Medicines slips after announcing equity offering plans - TradingView — Track All Markets
Praxis Precision Medicines announces proposed public offering By Investing.com - Investing.com India
Praxis Precision Medicines, Inc. Announces Proposed Public Offering - The Manila Times
Praxis Precision Medicines stock falls on proposed public offering By Investing.com - Investing.com India
Praxis Precision Medicines stock rises as FDA grants breakthrough designation By Investing.com - Investing.com South Africa
Praxis Precision Medicines stock rises as FDA grants breakthrough designation - Investing.com Australia
Praxis Precision Medicines (PRAX) Gets a Buy from Chardan Capital - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines stock gains as TD Cowen reiterates Buy on FDA breakthrough status - Investing.com Canada
Praxis Precision Medicines stock gains as TD Cowen reiterates Buy on FDA breakthrough status By Investing.com - Investing.com South Africa
Praxis: Priced For Perfection Heading Into 2026 (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines stock falls on proposed public offering - Investing.com
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug - ts2.tech
Praxis Precision Medicines stock gets FDA boost as H.C. Wainwright maintains Buy - Investing.com Canada
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.4%Here's Why - MarketBeat
Praxis Precision (PRAX) Shares Drop Amid Market Movement - GuruFocus
Truist Securities reiterates Buy rating on Praxis Precision Medicines stock By Investing.com - Investing.com Canada
Truist Securities reiterates Buy rating on Praxis Precision Medicines stock - Investing.com India
Praxis Precision granted Breakthrough Therapy designation for Ulixacaltamide - Yahoo Finance
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target - ts2.tech
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug - ts2.tech
Praxis Precision Medicines Stock Pre-Market (+12%) : FDA Breakthrough Therapy Designation for Ulixacaltamide - Trefis
Praxis Precision Medicines Stock Surges: What Drives the Wave? - StocksToTrade
Why Praxis Precision Medicines Stock Popped Today - Finviz
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Praxis Precision Medicines Inc-Aktie (PRAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):